The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

January 15, 2025

Eczema-linked protein helps cancer survive, suggesting potential for skin drug-based treatment.

January 13, 2025

Research from the Icahn School of Medicine at Mount Sinai provides new insights into acute myeloid leukemia (AML) and its resistance to a common treatment.

January 09, 2025

Nina Bhardwaj, MD, PhD, of Mount Sinai has been elected to the National Academy of Medicine for her pioneering work in cancer immunotherapy.

January 07, 2025

Genetic markers for venetoclax could help personalize treatment and improve outcomes

December 23, 2024

With a focus on closing gaps in cancer care for underserved populations, Joseph A. Sparano, MD, FACP, always strives to put patients first—a quality that has become a hallmark of his research and career in oncology.

December 19, 2024

Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.

November 26, 2024

Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.

November 26, 2024

Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

November 26, 2024

Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.

November 26, 2024

Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.

November 26, 2024

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

October 07, 2024

Joseph A. Sparano, MD, details the next generation of CDK inhibitors such as BLU-222 targeting CDK2 and PF-07220060 targeting CDK4.

October 07, 2024

Josep Llovet, MD, discusses the effiacy of TACE treatment with or without lenvatinib plus pembrolizumab in intermediate-stage hepatocellular carcinoma.

August 29, 2024

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

August 29, 2024

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

August 29, 2024

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

August 22, 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

August 22, 2024

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

August 15, 2024

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

August 15, 2024

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.